EZH2 and prostate carcinoma: It was demonstrated that EZH2 is overexpressed and/or harbors a gain-of-function mutations in solid tumors such as breast and prostate cancer as well in lymphomas and that these changes in EZH2 function are associated with shorter overall survival, progression of disease with development of metastasis and a higher TNM stage [7,8,9,10].